Investor Overview Press Releases September 17, 2019 Aclaris Therapeutics to Hold R&D Day September 16, 2019 Aclaris Therapeutics’ A-101 45% Topical Solution Meets Primary and All Secondary Efficacy Endpoints in Pivotal Phase 3 Trial for the Treatment of Common Warts (THWART-2) September 5, 2019 Aclaris Therapeutics Announces New Strategic Direction View all » Events Aug 8, 20195:00 PM EDT Q2 2019 Aclaris Therapeutics Inc. Earnings Conference Call Jul 30, 20195:00 PM EDT Aclaris Presents Top-Line Data from AUAT-201 Oral Phase 2 Trial Jun 26, 20195:00 PM EDT Aclaris Presents Top-Line Data from AA-201 Topical Phase 2 Trial View all » Feature presentation Immuno-dermatology Pipeline Presentation October 2017
September 16, 2019 Aclaris Therapeutics’ A-101 45% Topical Solution Meets Primary and All Secondary Efficacy Endpoints in Pivotal Phase 3 Trial for the Treatment of Common Warts (THWART-2)
